Its latest quarterly revenue reached 147.44M, representing a year-over-year increase of 41.22%, while its net profit experienced a year-over-year increase of 86.97%.
The current valuation score of Oncology Institute Inc is 7.50. Its current P/E ratio is -14.39, which is -12805.17% below the recent high of 1827.96 and -22.42% above the recent low of -17.61.
The current earnings forecast score of Oncology Institute Inc is 8.40. The average price target is 6.50, with a high of 8.00 and a low of 5.00.
The current price momentum score of Oncology Institute Inc is 4.95. Currently, the stock price is trading between the resistance level at 6.30 and the support level at 4.33, making it suitable for range-bound swing trading.
The latest institutional shareholding proportion is 47.57%, representing a quarter-over-quarter increase of 17.31%. The largest institutional shareholder is James Simons, holding a total of 1.37M shares, representing 0.01% of shares outstanding, with 2292.04% increase in holdings.
The current risk assessment score of Oncology Institute Inc is 3.74. The company's beta value is 0.39. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.